Nu kommer det som jag i över ett års tid varnat för!:
https://onlinelibrary.wiley.com/doi/10.1111/imm.13443
New-onset autoimmune phenomena post-COVID-19 vaccination
Recently, new-onset autoimmune phenomena after COVID-19 vaccination have been reported increasingly (e.g. immune thrombotic thrombocytopenia, autoimmune liver diseases, Guillain–Barré syndrome, IgA nephropathy, rheumatoid arthritis and systemic lupus erythematosus). Molecular mimicry, the production of particular autoantibodies and the role of certain vaccine adjuvants seem to be substantial contributors to autoimmune phenomena. In addition to the complications described above, other autoimmune manifestations have been reported in some cases, such as SLE, lupus nephritis and Graves' disease.
Different new-onset autoimmune phenomena following diverse COVID-19 vaccines:
Vaccine-induced immune thrombotic thrombocytopenia - Adenovirus vector vaccine and mRNA vaccine
Immune thrombocytopenic purpura - mRNA vaccine
Autoimmune liver diseases - mRNA vaccine and Adenovirus vector vaccine
Guillain–Barré syndrome - mRNA vaccine and Adenovirus vector vaccine
IgA nephropathy - mRNA vaccine
Autoimmune polyarthritis - mRNA vaccine
Rheumatoid arthritis - mRNA vaccine and Adenovirus vector vaccine
Graves' disease - mRNA vaccine
Type 1 diabetes mellitus - mRNA vaccine
Systemic lupus erythematosus - Adenovirus vector vaccine
The plausible mechanisms by which COVID-19 vaccines lead to autoimmune manifestations include molecular mimicry, the production of particular autoantibodies and the role of certain vaccine adjuvants.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618727/
Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome?
Multisystem inflammatory syndrome (MIS) is a new systemic inflammatory acute onset disease that mainly affects children (MIS-C) and, at a lesser frequency, adults (MIS-A); it typically occurs 3–6 weeks after acute SARS-CoV infection. It has been postulated and shown in adults that MIS may occur after SARS-CoV-2 vaccination (MIS-V). Our current case is one of the first published cases with a multisystem inflammatory syndrome in an 18-year-old adolescent after the SARS-CoV-2 vaccine from Pfizer/BionTech (BNT162b2), who fulfills the published level 1 criteria for a definitive disease.
Based upon our report, regarding elevated functional autoantibodies against G-protein-coupled receptors in children with MIS-C, we performed this autoantibody analysis in a research laboratory and found a comparable pattern of autoantibodies in the current patient after SARS-CoV-2 vaccination.
Together with our published data about elevated functional autoantibodies against G-protein-coupled receptors in children with MIS-C, the current case reports after vaccination show a comparable effect on the network of autoantibodies, and different autoantibodies uniformly shift to enhanced blood levels after the immunological response to the vaccine, comparable to our data after the natural infection. In both cases, the spike protein is the target of the immune response.
Autoantikropparna från vaccinet är identiska med de man får från infektion:
https://www.ncbi.nlm.nih.gov/pmc/art...ort=objectonly
Conclusion: We are aware that a misattribution of MIS-V as a severe complication of coronavirus vaccination can lead to increased vaccine hesitancy and blunt the global COVID-19 vaccination drive. It seems not to be the whole virus but the spike protein that induces autoimmunity, the most imminent danger for children in this pandemic.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323360/
Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V)
https://www.medrxiv.org/content/10.1....03.22268681v1
Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) Aged 12–20 Years in the United States Who Received COVID-19 Vaccine, December 2020 through August 2021
Så går det när ni inte lyssnar på dr. Saundra